Results 121 to 130 of about 28,823 (297)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Alogliptin benzoate for management of type 2 diabetes
Vascular Health and Risk Management, 2015 Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton +11 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − < 5000 mg/g, estimated glomerular ...
Janet B. McGill +15 more
wiley +1 more source
A STUDY ON THE CURRENT PRESCRIBING PATTERNS OF DIPEPTIDYL PEPTIDASE 4 INHIBITORS IN A MULTI SPECIALITY HOSPITAL OUTPATIENT SETTING [PDF]
, 2014 Objective: To evaluate the current prescribing pattern of dipeptidyl peptidase 4 inhibitors in a multi specialty hospital outpatient setting.Method: The study was a retrospective descriptive analysis of consecutive patients with DPP4 inhibitors ...
SATYANARAYANA, V. +5 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen +10 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim +5 more
wiley +1 more source